Proxalutamide - Suzhou Kintor Pharmaceuticals

Drug Profile

Proxalutamide - Suzhou Kintor Pharmaceuticals

Alternative Names: GT-0918

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Suzhou Kintor Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase I Breast cancer

Most Recent Events

  • 16 Jul 2018 The Chinese Center for Drug Evaluation accepts clinical programme for proxalutamide for priority review (Suzhou Kintor Pharmaceuticals website, July 2018)
  • 01 Jul 2018 Phase-I clinical trials in Breast cancer in China (PO) (Suzhou Kintor Pharmaceuticals pipeline, July 2018)
  • 01 Jul 2018 Phase-I clinical trials in Breast cancer in USA (PO) (Suzhou Kintor Pharmaceuticals pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top